Moderna, Inc.
NASDAQ:MRNA · NASDAQ Global Select
+$2.48 today
Vol 21.59M · Avg 6.53M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-32.6%
avg -13.4%
ROIC
-29.7%
avg -11.1%
ROA
-22.9%
avg -9.3%
Analysis
ROA is currently the strongest return metric at -22.9% versus its period average of -9.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Stéphane Bancel | Chief Executive Officer & Director | $6.14M | — | 53 | $250,932.00 | 0.06% |
Stephen Hoge | President | $4.26M | — | 50 | $1.52M | 0.38% |
Shannon Thyme Klinger | Chief Legal Officer & Corporate Secretary | $2.18M | — | 55 | $117,976.00 | 0.03% |
James Mock | Chief Financial Officer | $2.18M | — | 49 | $65,687.00 | 0.02% |
Lavina Talukdar | Senior Vice President & Head of Investor Relations | — | — | 52 | — | — |
Tracey Franklin | Chief People & Digital Technology Officer | — | — | 46 | — | — |
Charbel Haber | Senior Vice President & Head of Global Regulatory Science | — | — | — | — | — |
Jerh Collins | Chief Technical Operations & Quality Officer | — | — | 60 | — | — |
John Lepore | Senior Vice President of Government Engagement | — | — | — | — | — |
José Vega | Chief Safety Officer | — | — | — | — | — |
Patrick Norman Bergstedt | Senior Vice President of Commercial Vaccines | — | — | 64 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
9
$15.45M
Net Sentiment
$15.45M
Net selling
Most Active
Hoge Stephen
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 9 sells worth $15.45M over the last 12 months. That adds up to net selling of $15.45M. Hoge Stephen was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A7 analysts |
| Revenue | N/A | N/A | +57.5% | +23.8% (10yr)9 analysts |
| Net Income | N/A | N/A | N/A | N/A9 analysts |
| EBIT | N/A | N/A | N/A | N/A9 analysts |
Analysis
Recent growth has been strongest in Revenue at +57.5% over three years. Forward estimates point to Revenue at +23.8% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$34.84B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.12B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.04B
Exelixis, Inc.
NASDAQ:EXEL
$13.01B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.64B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.54B
Bio-Techne Corporation
NASDAQ:TECH
$9.01B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.05B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.23B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$217.24M
Who manages MRNA?
Moderna, Inc. (MRNA) lists 11 active executives. The top listed executive is Stéphane Bancel, Chief Executive Officer & Director.
Are MRNA insiders buying or selling?
Recent insider activity shows net buying of $5.49M.
Explore More
Continue the stock analysis
Jump to another research area for this company.